A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China
出版年份 2023 全文链接
标题
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China
作者
关键词
-
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-06
DOI
10.1007/s13300-023-01496-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
- (2021) Hong Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Design, Synthesis and Evaluation of a Series of Novel Super-long Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
- (2020) Chen Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Genetics of diabetes mellitus and diabetes complications
- (2020) Joanne B. Cole et al. Nature Reviews Nephrology
- The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
- (2020) Anca Pantea Stoian et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
- (2020) Carolyn F. Deacon Nature Reviews Endocrinology
- Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018
- (2019) Sara Ramzan et al. Primary Care Diabetes
- Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
- (2019) Zhaoliang Li et al. Frontiers in Pharmacology
- QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
- (2019) Suhas Erande et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?
- (2017) Kashif M. Munir et al. EXPERT OPINION ON PHARMACOTHERAPY
- Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
- (2017) Michaela Luconi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
- (2016) David W. Boulton CLINICAL PHARMACOKINETICS
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
- (2016) Jan W. Eriksson et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
- (2016) Charles E. Grimshaw et al. PLoS One
- Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes
- (2015) Wayne H.-H. Sheu et al. DIABETES CARE
- Once-weekly DPP-4 inhibitors: do they meet an unmet need?
- (2015) André J Scheen Lancet Diabetes & Endocrinology
- DPP-4 inhibitors: focus on safety
- (2014) Sri Harsha Tella et al. Expert Opinion On Drug Safety
- Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
- (2014) Paul Craddy et al. Diabetes Therapy
- The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
- (2011) Arne Ring et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
- (2011) Carl Asche et al. CLINICAL THERAPEUTICS
- A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
- (2009) Daniel M. Bloomfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search